Establishment Labs Holdings Inc. · NASDAQ:ESTA
Establishment Labs — 41st Annual J.P. Morgan Healthcare Conference (January 2023)
33 slides from Establishment Labs's conference presentation, Jan 12, 2023
Slide 1: 41st Annual J.P. Morgan Healthcare Conference
41 Annual J.P. Morgan st Healthcare Conference JANUARY 12th, 2023 JUAN JOSÉ CHACÓN-QUIRÓS Founder & CEO Establishment Labs
Slide 2: Forward Looking Statements and Other Legal Matters
FORWARD LOOKING STATEMENTS AND OTHER LEGAL MATTERS This presentation contains forward-looking statements within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934. Any statements that refer to projections of our future financial or operating performance, anticipated tr
Slide 3: Establishment Labs: Our Purpose
ESTABLISHMENT LABS A global medical device company dedicated to improve Women’s health and wellness. OUR PURPOSE Putting Women First: in health and well-being, in science and technology, and in our communities. < 03 >
Slide 4: Breast Implant Industry Market and Challenges
BREAST IMPLANT INDUSTRY MARKET CHALLENGES Global breast implant market is approximately Lack of innovation $2.0 - $2.2B annually Breast augmentation is the #1 aesthetic Male-centered industry surgical procedure worldwide, with over 1.6 million performed annually $1.5B Insufficient safety Breast reco
Slide 5: Growth Story: Heal, Normalize, Democratize
GROWTH STORY HEAL NORMALIZE DEMOCRATIZE Offer new and differentiated Offer safer and innovative Improve outcomes and technologies that overcome options for women seeking expand access to breast current perceptions and breast aesthetics reconstruction behaviors in breast aesthetics Create new categor
Slide 6: Healing Breast Aesthetics
HEALING BREAST AESTHETICS < 06 >
Slide 7: Company history and product launches
2004 2010 Company founded Product Launch Advanced SmoothSilk® TrueMonobloc® Technology links the and research started. Launched Motiva Implants®. / SilkSurface®design for a components of the shell and the filling gel to biocompatible visual barrier layer. create a more cohesive structure. 2011 2012
Slide 8: Pioneering Biocompatible Surface Technology
PIONEERING HIGH-DURABILITY PROPRIETARY UNIQUE SILICONE BIOCOMPATIBLE SILICONE SHELL AND SAFETY-FOCUSED FORMULATIONS AND SURFACE TECHNOLOGY IMPLANT CONSTRUCTION TECHNOLOGIES ERGONOMIC DESIGN SmoothSilk® patent TrueMonobloc® This Qid®, an embedded RFID Ergonomix® proprietary protected technology is a
Slide 9: Implants sold, countries, inventions
+ 2,500,000 implants sold globally since Motiva Implants® commercial launch in 2010 +85 Countries where Motiva Implants® have been approved +25 Inventions (patent families) and 218 applications globally in 21 jurisdictions Less than 1% device-related complications <1 < 09 >
Slide 10: Post-Market Surveillance
POST-MARKET SURVEILLANCE Adverse Events by Type Since 2010 Device-Related Capsular Double BIA- BIA- Latrogenic Technique-Dependent Rupture Other** Contracture Capsule ALCL SCC Rupture Complications* 0.022% 0.000% 0.000% 0.000% 0.000% 0.037% 0.003% 0.004% N:535 N:0 N:0 N:0 N:0 N:918 N:71 N:71 <1 % de
Slide 11: Comparative Breast Implant Industry Data
SIENTRA ALLERGAN MENTOR (N=1,115) (N=455) (N=552) Capsular contracture III/IV 6.0% 10.7% 8.1% COMPARATIVE Rupture MRI Cohort (Susp/ Conf) 2.5% 2.0% 0.5% 3 YEAR DATA DATA BREAST Breast Pain 0.8% 8.3% 1.7% Infection 0.7% <1.0% 1.5% IMPLANT Implant Malposition 1.2% 5.4% 0.4% Explantation (with/without
Slide 12: Motiva US IDE Study Kaplan-Meier
Motiva® US IDE STUDY Motiva®KAPLAN-MEIER 2-YEAR KEY COMPLICATIONS Primary Augmentation 2-year (N=451), 95% CI 1. Capsular Contracture (baker III/IV) 0.5% 2. Rupture, suspected or confirmed 0.3% 3. Breast Pain 0.5% 4. Infection 0.9% 5. Implant removal, with or without replacement 1.6% 6. Any reoperat
Slide 13: The Science Behind These Outcomes
THE SCIENCE BEHIND THESE OUTCOMES 25 peer-reviewed scientific publications < 13 >
Slide 14: Breast Implant Surface Research in Nature Biomedical Engineering
SUMMARY PUBLICATION OF LANDMARK BREAST IMPLANT SURFACE RESEARCH IN NATURE BIOMEDICAL ENGINEERING These findings suggest that SmoothSilk®/SilkSurface® provoked the least amount of Surface architecture is an inflammation and FBR across influential parameter in mouse and rabbit models, controlling the
Slide 15: Beyond Clinical Outcomes: Improved Aesthetic Outcomes
BEYOND CLINICAL OUTCOMES: IMPROVED AESTHETIC OUTCOMES Concept of ergonomy Hybrid surgery Small incisions < 15 >
Slide 16: Total Global Aesthetic Breast Implant Market
TOTAL GLOBAL AESTHETIC BREAST IMPLANT MARKET ~$1.5 BILLION ESTA COMPETES IN LESS THAN 1/2 OF THE GLOBAL MARKET ENTRY INTO REMAINING WITH 33% SHARE IN THOSE MAJOR GLOBAL MARKETS MARKETS AND GROWING UNITED STATES • ~40-50% of the global aesthetic market • Modules 1, 2 and 3 have been submitted to the
Slide 17: Normalizing Breast Aesthetics
NORMALIZING BREAST AESTHETICS < 17 >
Slide 18: Expanding the Market
EXPANDING THE MARKET Opportunity to create a new category that addresses unmet needs in breast aesthetics CONSUMER INSIGHTS Of women are somewhat Of consumers worldwide report 76% dissatisfied or think their bodies 54% they will keep trying to achieve the can have a better shape.1 vision they have f
Slide 19: Mia brings harmony to the woman's body
Mia® brings harmony to the woman’s body with a naturally discrete proportional result + + using breakthrough In a 15 minutes1 and no general minimally invasive procedure anesthesia technologies so that women can get on with their busy lives* 1.Establishment Labs®. Data on file. CLINR-001018 *Exercis
Slide 20: Mia Femtech product components
Ergonomix2 Diamond® Implants Motiva Injector® Motiva® Channel Dissector Motiva® Inflatable Motiva® Marking Tool Balloon
Slide 21: She Got Married 3 Days After Mia Femtech
“I decided to trust that the recovery process would be quick and it exceeded all my expectations. SHE GOT MARRIED 3 DAYS My Big Day Was Perfect.” AFTER MIA FEMTECH™ Carolina - 30 years Engineer < 21 >
Slide 22: Key Facts Market Opportunity
KEY FACTS MARKET OPPORTUNITY 11x more women would ~73% Mia® candidates are Mia® consumers are choose Mia® over other currently not considering willing to pay 2x over traditional breast other traditional breast other traditional breast augmentation procedures augmentation procedures augmentation proc
Slide 23: Japan Market Sizing
Target Market for the Mia® concept (Not implanted, Cup A/B) JAPAN 2.2M I 50% MARKET SIZING Concept Appeal 490K I 22% Women 25-54 with income >¥6M Represents 4.4M women in Japan Interested in Mia® procedure 155K I 32% The survey yields an estimate of 155,000 women with less than C cup Purchase intent
Slide 24: Mia Femtech Proof of Concept
MIA FEMTECH™ PROOF OF CONCEPT Case series done in early 2022 showing reality of performing 10 patients in under 5 hours Start time 8:10 am 10-Patient Average 27 minutes Average skin-to-skin procedure time End time 12:48 pm Average discharge time 12 minutes 8 minutes Total time 10 cases 4hr38min Aver
Slide 25: Global Total Addressable Market with Mia
2021: Global total addressable Market with Mia® Mia® I Creates $6 Billion in Annual Addressable Market Traditional Breast Augmentation Market New potential Market Combined Breast implant augmentation procederes Mia ® procedures Procedures 1.6M 1.9M 2.7M 1 50% NEW consumers Total addressable market T
Slide 26: Democratizing Breast Reconstruction
DEMOCRATIZING Breast Reconstruction < 26 >
Slide 27: An Evolution: Aesthetic BreastRecon
AN EVOLUTION Aesthetics Reconstruction Safety Aesthetic BreastRecon® Enable women to receive a standard of care that achieves the aesthetic outcomes they aspire to after breast cancer. < 27 >
Slide 28: Flora Raising the Standard of Care
FLORA RAISING THE STANDARD OF CARE ® OUR FIRST TECHNOLOGY TO TRANSFORM BREAST RECONSTRUCTION < 28 >
Slide 29: Aesthetic BreastRecon
Aesthetic BreastRecon® Can expand access and acceptance of breast reconstruction worldwide Approximately 1.67 million new cases are diagnosed worldwide, and over 500,000 women die of the disease each year. FDA studies show a complication rate of 30%+ in breast reconstruction procedures In developed
Slide 30: Our Third Facility
OUR THIRD FACILITY (Under final stage of construction) will expand our capacity by one million units per year Expected to start operations in 2023 < 30 >
Slide 31: Delivering Growth
DELIVERING GROWTH Growing organically in our existing markets $ 43.3 - $44.3 2022 PREANNOUNCED REVENUE RANGE: $161.2M to $162.2M1 $41.2 CONSTANT REVENUE GROWTH: 31% to 32% $38.5 $38.2 $35.3 $32.0 $30.3 $29.0 $26.9 $24.2 $24.5 $22.8 $22.9 $21.7 $20.8 $16.3 $16.4 $14.8 $13.7 $11.8 $10.5 $8.6 $6.9 $7.3
Slide 32: Beyond 2022
BEYOND 2022 Targeting $500M in Annual Revenue in Fiscal 2026 Expecting an average rate of growth of 33% per year over the next 4 years, and significant growth beyond ~$162M $500M 2022 2026 < 32 >
Slide 33: Thank you
Thank you f
Establishment Labs Holdings — 41st Annual J.P. Morgan Healthcare Conference (January 2023) on 6ix